Clinical trials: Nevirapine
HIV Infections
Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
Primary purpose of this study is to compare the efficacy and safety of two different nevirapine (Viramune) dosing regimens (once daily (QD) and twice daily (BID) application) and of atazanavir/ritonavir (Reyataz/Norvir), all on…
- Trial name
- NCT00389207
- Testing
- nevirapine bid, nevirapine qd, atazanavir
- Where
- 68 sites in Argentina, Germany and 8 more
- Volunteers
- 576 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR) in ARV therapy naïve HIV-1 infected patients…
- Trial name
- NCT00561925
- Testing
- nevirapine IR, nevirapine XR
- Where
- 202 sites in United States, Argentina and 19 more
- Volunteers
- 1,068 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
The primary objective is to establish the pharmacokinetic (PK) profile at steady state of nevirapine XR in HIV infected children from >=3 to <18 years of age.
- Trial name
- NCT00905489
- Testing
- Nevirapine Immediate Release (IR), Nevirapine Extended Release (XR)
- Where
- 10 sites in United States, Botswana and 2 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data
The question that prompted this study is the extent to which results from clinical trials can be translated into everyday practice (external validity).
- Trial name
- NCT01134939
- Where
- 34 sites in Germany
- Volunteers
- 265 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)
The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).
- Trial name
- NCT00552240
- Testing
- tenofovir DF 300 mg QD, emtricitabine 200 mg QD, Nevirapine 200 mg BID
- Where
- 19 sites in United States
- Volunteers
- 154 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
This Post Marketing Surveillance study will be performed as an open-label, prospective, non-interventional, uncontrolled study in Human immunodeficit Virus-1 (HIV-1) infected patients.
- Trial name
- NCT01524900
- Where
- 53 sites in Austria, Poland and 1 more
- Volunteers
- 398 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune
The question that prompted this study is the extent to which results from clinical trials can be translated into everyday practice (external validity).
- Trial name
- NCT00979420
- Where
- 60 sites in Germany
- Sponsor
- Boehringer Ingelheim
HIV Infections
Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients
This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Viramune (nevirapine) in combination with Truvada (tenofovir and emtricitabine) will durably suppress…
- Trial name
- NCT00543803
- Where
- 63 sites in Germany
- Volunteers
- 334 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
To evaluate changes in renal function, efficacy, and safety when switching from a combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r) to a combination of raltegravir (MK-0518) plus…
- Trial name
- RANIA (NCT02116660)
- Testing
- Raltegravir (MK-0518), Nevirapine, Lamivudine
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Viramune® on a background of different antiretroviral drug combinations.
- Trial name
- NCT00736502
- Where
- 17 sites in Austria, Poland
- Volunteers
- 280 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients
The primary objective of this study is to demonstrate the efficacy of nevirapine extended release (NVP XR) based regimen for HIV-1 infected patients who were receiving nevirapine immediate release (NVP IR) based regimen for at…
- Trial name
- NCT00819052
- Testing
- Nevirapine XR, Nevirapine IR
- Where
- 39 sites in United States, France and 2 more
- Volunteers
- 445 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Viramune (nevirapine) in combination with ARV, e.g.
- Trial name
- NCT00876733
- Where
- 66 sites in Germany
- Volunteers
- 605 people
- Sponsor
- Boehringer Ingelheim